Ruzasvir
- Generic Name
- Ruzasvir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C49H55FN10O7S
- CAS Number
- 1613081-64-3
- Unique Ingredient Identifier
- LX752BD95Y
- Background
Ruzasvir has been used in trials studying the treatment of Hepatitis C, Hepatitis C, Chronic, and Hepatitis C Infection.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 275
- Registration Number
- NCT05904470
- Locations
- 🇹🇷
Atea Study Site, Kayseri, Turkey
Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 282
- Registration Number
- NCT02956629
A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT02666352
Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 443
- Registration Number
- NCT02332707
Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 413
- Registration Number
- NCT02332720
Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT02076100
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath